News & Updates

Show Multimedia Only
Long-term benefits with molnupiravir modest at best in COVID-19 treatment

Long-term benefits with molnupiravir modest at best in COVID-19 treatment

24 Sep 2024 byJairia Dela Cruz

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

24 Sep 2024
What fuels flu, pneumococcal vaccine hesitancy in SG?

What fuels flu, pneumococcal vaccine hesitancy in SG?

23 Sep 2024 byJairia Dela Cruz

In Singapore, influenza and pneumococcal vaccination coverage remains stubbornly low. Results of two separate analysis of a cross-sectional survey shed light on this concerning trend, highlighting the roles of vaccine knowledge and attitude, healthcare professionals, and social support in influencing vaccination decisions.

23 Sep 2024
COVID-19 variants carry no increased autoimmune sequelae risk

COVID-19 variants carry no increased autoimmune sequelae risk

16 Sep 2024 byJairia Dela Cruz

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

16 Sep 2024